



Application No.: 09/841,091

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable and/or unacceptable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: Sequences in the specification must contain a SEQ ID NO. Please amend:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**RECEIVED**

JUL 09 2003

TECH CENTER 1600/2900

Express Mail Label No.: EV528702466US

Date of Deposit: July 2, 2003

Attorney Docket No. 18475-034 (NEMC-215)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Kuliopulos and Covic  
SERIAL NUMBER: 09/841,091 EXAMINER: Sandra L. Wegert  
FILING DATE: April 23, 2001 ART UNIT: 1647  
FOR: G PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS  
AND ANTAGONISTS AND METHODS OF ACTIVATING  
AND INHIBITING GPCR USING THE SAME

MAIL STOP SEQUENCE

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RECEIVED

JUL 09 2003


TECH CENTER 1600/2900

STATEMENT IN SUPPORT OF COMPUTER READABLE  
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper copy and computer readable forms of the  
Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. §  
1.821(c) and 1.821(e), respectively, are the same. No new matter is added.

Respectfully submitted,

July 2, 2003

  
Gregory J. Sietzkiewicz, Reg. No. 48,223  
Agent for Applicant  
c/o Mintz, Levin  
One Financial Center  
Boston, MA 02111  
Telephone (617) 542 6000  
Fax : (617) 542 2241